Market Flux Event
CG Oncology PIVOT-006 Phase 3 Delivers 68% Recurrence Risk Reduction in Bladder Cancer as Jefferies and UBS Conferences Draw Sector to London
Read this in the Market Flux appCG Oncology reported positive topline results from its PIVOT-006 Phase 3 registrational trial on November 16, showing that adjuvant intravesical cretostimogene grenadenorepvec cut the risk of recurrence by 68% compared with the control arm in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer. The trial, which enrolled 367 patients in a randomized 1:1 open-label design comparing cretostimogene following TURBT against surveillance or TURBT alone, produced a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p less than 0.0001). The safety profile was described as compelling, with no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations, and topline results were scheduled for a late-breaking podium presentation.
Also on November 16, Lantheus presented data from two pivotal Phase 3 studies of its FDA-approved tau PET imaging agent TAUKLARIFY (florquinitau F 18 injection) at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 meeting. The studies demonstrated high sensitivity, specificity and inter-reader agreement for detecting tau pathology in early Alzheimer's disease, using a novel prospectively defined clinical radiological reference standard. TAUKLARIFY had received FDA approval in August 2026, making the CTAD data its first major post-approval scientific showcase.
The clinical readouts arrived as two major investor events, the Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference, convened in London. Both conferences drew a broad cross-section of biopharmaceutical and healthcare companies including BridgeBio Pharma, Revolution Medicines, Vertex Pharmaceuticals, Ionis Pharmaceuticals, United Therapeutics, Dianthus Therapeutics, ImmunityBio, Iovance, Kiniksa, Axsome Therapeutics, Viridian Therapeutics, Allogene, PTC Therapeutics, Tyra Biosciences, CONMED and Essity, among others. Essity, the Swedish hygiene and health company, highlighted growth initiatives alongside margin pressures in its Jefferies appearance. Nuvation Bio used the Jefferies forum to present long-term data on its brain cancer drug.
© AI-generated summary is provided by Market Flux
Sources
- Business WireTurn Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Seeking AlphaBioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
- InvestingViridian Therapeutics at Jefferies conference: launch gains and pipeline depth
- GurufocusBioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
- TheTradeXchange$CGON - PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
- Investors Business DailyCG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
- BarronsonlineCG Oncology stock is on pace for a record closing high after ‘best case’ Phase 3 trial results for its bladder cancer treatment.
- Schaeffers Research2 Cancer-Drug Developers Seeing Unusual Options Volume
Show 5 more
- MarketRebelsCG Oncology $CGON #UOA jumps as its bladder cancer treatment cuts the risk of the cancer coming back by 68% in a late-stage trial @petenajarian @jonnajarian follow the science because #ITSNOTANOPTION 📙 Rebel Investors Club daily market briefings 3 months free 👉
- Proactive_XMarket movers: Intel, Telus, Summit Therapeutics, Grey Matters Health...
- CnbcEli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia
- NasdaqAstraZeneca PLC Receives US FDA Approval for Imfinzi Combination in Muscle-Invasive Bladder Cancer
- ReutersUS FDA approves Roche's oral treatment for advanced breast cancer